Drug intelligence / Profile preview

Bi-haemosol

Development stage: Unknown
Lead developer: Duopharma
Modality: Small Molecules
Administration: Parenteral

Overview

Bi-haemosol is a bicarbonate-based hemodialysis concentrate developed by Duopharma Biotech. It is indicated for the treatment of patients with acute or chronic renal failure, including End-Stage Renal Disease (ESRD), who require hemodialysis. The product is typically supplied as a two-part system consisting of an acid concentrate (containing electrolytes like sodium, potassium, calcium, magnesium, and acetic acid) and a bicarbonate concentrate. During the dialysis process, these components are diluted and mixed to form the dialysate, which facilitates the removal of metabolic waste products (such as urea and creatinine) and the restoration of electrolyte and acid-base balance across a semi-permeable membrane.

Brand names: Bi-haemosol
Other names: Bicarbonate hemodialysis concentrate

Beyond the preview

Go deeper on Bi-haemosol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bi-haemosol.

Explore the full profile